35 completed. 35 Phase 2, 9 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 35 | Completed 35 |
| Phase 1 | 9 | Completed 9 |
| Phase 3 | 3 | Completed 3 |
Follow Musculoskeletal Abnormalities: new trials by email Literature Review of Musculoskeletal Abnormalities trials Research Report on Musculoskeletal Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Augmented Reality for Orthognatic Surgery Patient Education Patient consultation - Malocclusion, Dentofacial Deformities | Phase 2 / Phase 3 | Completed | University Medical Center Groningen | 60 | 2023-10-01 | 2025-03-30 |
| Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration Pemigatinib - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Completed | Incyte Corporation | 8 | 2022-04-29 | 2025-08-05 |
| NB-001 in Children and Adolescents With 22q11 Deletion Syndrome NB-001, Placebo - 22q11 Deletion Syndrome | Phase 2 | Completed | Nobias Therapeutics, Inc. | 37 | 2022-02-10 | 2025-02-10 |
| Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE) ZYN002 - 22Q11.2 Deletion Syndrome | Phase 2 | Completed | Harmony Biosciences Management, Inc. | 20 | 2020-02-19 | 2026-03-09 |
| A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion E7090 - Cholangiocarcinoma | Phase 2 | Completed | Eisai Co., Ltd. | 63 | 2020-01-22 | 2026-03-02 |
| Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety Rogaratinib (BAY1163877), Combination drug - Cancer | Phase 2 | Completed | Bayer | 1 | 2019-10-30 | 2022-04-01 |
| Derazantinib and Atezolizumab in Patients With Urothelial Cancer Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily+ atezolizumab 1200 mg - Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | Basilea Pharmaceutica | 95 | 2019-08-02 | 2023-10-13 |
| Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC RMC-4630, Cobimetinib, Drug: Osimertinib - Solid Tumor | Phase 1 / Phase 2 | Completed | Revolution Medicines, Inc. | 113 | 2019-07-02 | 2023-06-26 |
| The Efficacy and Safety of Chloroprocaine 1% and 2% in Pediatric Population Chloroprocaine 1% Injectable Solution, Chloroprocaine 2% Injectable Solution - Hernia, Inguinal, Flat Foot | Phase 2 | Completed | Sintetica SA | 164 | 2019-02-14 | 2026-03-23 |
| A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China JAB-3068 - Non-small Cell Lung Cancer, Head and Neck Cancer | Phase 1 / Phase 2 | Completed | Jacobio Pharmaceuticals Co., Ltd. | 126 | 2018-11-20 | 2024-09-25 |
| Suprazygomatic Block in Cleft Palate Surgery in Children Bupivacaine, Dexmedetomidine, paracetamol - Cleft Palate | Phase 2 | Completed | Assiut University | 80 | 2018-01-14 | 2018-09-24 |
| Does it Worth to Reinforce With Additional Anesthesia to Improve Postoperative Course After Orthognathic Surgery? Second infiltration pre-extubation with ropivacaine - Dentofacial Deformities | Phase 2 | Completed | Servei Central d'Anestesiologia | 52 | 2018-01-10 | 2020-02-13 |
| Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) Pemigatinib - Cholangiocarcinoma | Phase 2 | Completed | Incyte Corporation | 147 | 2017-01-16 | 2025-08-14 |
| A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) pemigatinib - UC (Urothelial Cancer) | Phase 2 | Completed | Incyte Corporation | 263 | 2017-01-12 | 2025-08-14 |
| A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma Erdafitinib - Neoplasm | Phase 2 | Completed | Janssen Research & Development, LLC | 35 | 2016-07-08 | 2025-04-27 |
| Comparative Study Between Levobupivacaine and Bupivacaine for Nerve Block During Pediatric Primary Cleft Palate Surgery Levobupivacaine, Bupivacaine - Recovery After Cleft Palate Surgery | Phase 2 / Phase 3 | Completed | Assiut University | 60 | 2016-01-01 | 2017-09-07 |
| Botulinum Toxin to Improve Cosmesis of Primary Cleft Lip Repair Botulinum Toxin Type A, Normal Saline Injection - Cleft Lip, Scarring | Phase 1 / Phase 2 | Completed | The University of Texas Health Science Center, Houston | 30 | 2015-12-01 | 2021-11-03 |
| Compassionate Use of Omegaven in Children Omegaven - Total Parenteral Nutrition-induced Cholestasis, Cholestasis | Phase 2 / Phase 3 | Completed | University of Oklahoma | 63 | 2015-06-01 | 2019-11-25 |
| Description of Pain in Pediatric Patients With Cleft Lip and Palate Undergoing Alveolar Grafting Using Two Surgical Strategies: Stem Cells and Autogenous Iliac Crest Bone (Pain Evaluation in Children Undergoing Alveolar Grafting: Stem Cells vs. Iliac Crest Bone) Autogenous Iliac Crest Bone Grafting, Bioengineered Alveolar Grafting (SHED + Scaffold) - Clift Lip, Cleft Palate | Phase 1 / Phase 2 | Completed | Hospital Sirio-Libanes | 20 | 2015-03-01 | 2026-07-29 |
| Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes Mocetinostat - Urothelial Carcinoma | Phase 2 | Completed | Mirati Therapeutics Inc. | 17 | 2014-10-01 | 2017-09-01 |
Showing 20 of 35. Sign in to see all of them.
Cleft Palate (8) · Acrocephalosyndactylia (7) · DiGeorge Syndrome (6) · Carcinoma, Non-Small-Cell Lung (5) · Carcinoma, Transitional Cell (4) · Cleft Lip (4) · Cholangiocarcinoma (3) · Immunologic Deficiency Syndromes (3) · Neoplasms (3) · Thymic aplasia (3) · Colorectal Neoplasms (2) · Dentofacial Deformities (2) · Esophageal Neoplasms (2) · Head and Neck Neoplasms (2) · Hypocalcemia (2)
Congenital Abnormalities (35) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (35) · Musculoskeletal Diseases (34) · Craniofacial Abnormalities (31) · Bone Diseases (12) · Maxillofacial Abnormalities (12) · Stomatognathic Diseases (12) · Stomatognathic System Abnormalities (12) · Bone Diseases, Developmental (11) · Dysostoses (10) · Jaw Abnormalities (10) · Jaw Diseases (10) · Abnormalities, Multiple (9) · Carcinoma (9)
pemigatinib (3) · Bupivacaine (2) · Drug Implants (2) · Saline Solution (2) · Thymus Extracts (2) · 5-((2-(6-Amino-9H-purin-9-yl) ethyl) amino)-1-pentanol (1) · Acetaminophen (1) · Ampicillin (1) · Antilymphocyte Serum (1) · Blood Specimen Collection (1) · Botulinum Toxins, Type A (1) · Cyclosporine (1) · Cyclosporins (1) · Daclizumab (1) · Dexmedetomidine (1)
Incyte Corporation (3) · Sumitomo Pharma Switzerland GmbH (3) · Assiut University (2) · University of Oklahoma (2) · Basilea Pharmaceutica (1) · Bayer (1) · Eisai Co., Ltd. (1) · Harmony Biosciences Management, Inc. (1) · Hospital Sirio-Libanes (1) · Jacobio Pharmaceuticals Co., Ltd. (1) · Janssen Research & Development, LLC (1) · Joseph Losee (1) · Mirati Therapeutics Inc. (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Nobias Therapeutics, Inc. (1)
United States (20) · Spain (6) · France (5) · Germany (5) · Italy (5) · South Korea (4) · Brazil (3) · China (3) · Japan (3) · United Kingdom (3) · Australia (2) · Belgium (2) · Canada (2) · Egypt (2) · Israel (2)
M. Louise Markert, MD, PhD (3) · Daniela Francescato Veiga (1) · Daniela Y Tanikawa, MD (1) · Darnell Kaigler, DDS, PhD (1) · Ekaterine Asatiani, MD (1) · J Kraeima, dr. (1) · Jaecel O Shah, MD (1) · Joseph Losee, MD (1) · Kimberly D Ernst, MD, MSMI (1) · Kristen Bzdek, MD (1) · Lim K Cheung, BDS, PhD (1)
PMID 18035553, PMID 18424759, PMID 18557726, PMID 19066739, PMID 20236866, PMID 17284531, PMID 12702512, PMID 17763894, PMID 18155964, PMID 18513295, PMID 19912236, PMID 20443823, PMID 20978268, PMID 21120277, PMID 21565561, PMID 21999260, PMID 23117614, PMID 23607606, PMID 23914737, PMID 28688787, PMID 28748333, PMID 30570744, PMID 31599480, PMID 32203698, PMID 35544727, PMID 36206041, PMID 37956738, PMID 38039831, PMID 38627238, PMID 39138436, PMID 41888667, PMID 42069961, PMID 9628377
K12HD043494 (3), R01AI047040 (3), R01AI054843 (3), 2016 (2), 2019 (2), R56AI047040 (2), R01DE010437 (1)